World Journal of Gastrointestinal Pathophysiology · 2020 · 13 citations · 30 references
MedicinePathobiologyPharmacologyImmunopathologyInflammationMolecular PharmacologyGastrointestinal FunctionGastrointestinal InflammationGastrointestinal PathophysiologyGastrointestinal PharmacologyGastrointestinal PhysiologyInflammatory Bowel DiseaseEnteric InflammationEnteric Nervous System DysfunctionEnteric PathologyNitric OxideNitric Oxide Synthase RegulationP2x7 Receptor SignalingSham TreatmentUlcerative Colitis Pathology
BACKGROUND: The P2X7 receptor is expressed by enteric neurons and enteric glial cells. Studies have demonstrated that administration of a P2X7 receptor antagonist, brilliant blue G (BBG), prevents neuronal loss. AIM: . METHODS: = 5) was given subcutaneously 1 h after TNBS. The animals were euthanized after 24 h, and the ileum was removed. Immunohistochemistry was performed on the myenteric plexus to evaluate immunoreactivity for P2X7 receptor, neuronal nitric oxide synthase (nNOS), choline acetyltransferase (ChAT), HuC/D and glial fibrillary acidic protein. RESULTS: ) demonstrated that nNOS-ir neurons decreased in the TNBS group and recovered in the BBG group. There were no differences in the profile areas of ChAT- and HuC/D-ir neurons. CONCLUSION: Our data conclude that ileum myenteric neurons and glial cells were affected by ulcerative colitis and that treatment with BBG had a neuroprotective effect. Thus, these results demonstrate that the P2X7 receptor may be an important target in therapeutic strategies.
30
John B. Furness · 2008 · 539 citations
Brilliant Blue G Selectively Blocks ATP-Gated Rat P2X<sub>7</sub>Receptors
Lin‐Hua Jiang, Amanda B. Mackenzie, R. Alan North et al. · Molecular Pharmacology · 2000 · 405 citations